KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Repligen (RGEN) EBITDA (2016 - 2025)

Repligen (RGEN) has disclosed EBITDA for 16 consecutive years, with $14.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 128.7% to $14.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.9 million, a 331.83% increase, with the full-year FY2025 number at $98.9 million, up 345.77% from a year prior.
  • EBITDA was $14.9 million for Q4 2025 at Repligen, up from $12.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $69.6 million in Q4 2022 to a low of -$51.8 million in Q4 2024.
  • A 5-year average of $18.3 million and a median of $16.6 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 375.39% in 2024, then surged 3307.32% in 2025.
  • Repligen's EBITDA stood at $22.1 million in 2021, then soared by 214.3% to $69.6 million in 2022, then plummeted by 115.65% to -$10.9 million in 2023, then crashed by 375.39% to -$51.8 million in 2024, then soared by 128.7% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for RGEN's EBITDA are $14.9 million (Q4 2025), $12.5 million (Q3 2025), and $61.0 million (Q2 2025).